ABBV-400 for Non-Small Cell Lung Cancer
This trial is testing the investigational drug ABBV-400 to see if it is effective and safe in treating advanced solid tumors.
- Non-Small Cell Lung Cancer
- Solid Tumors
- Gastroesophageal Adenocarcinoma
- Colorectal Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many participants are being admitted for this clinical experiment?
"This medical experiment calls for 220 qualified patients to enrol. Those looking to participate can head over to START Midwest in Grand Rapids, Michigan (ID# 231551) or Community Health Network, Inc. /ID# 245331 which is located in Indianapolis, Indiana)."
Are there multiple sites that are conducting this experiment?
"Patients are presently being recruited across 9 different medical sites, which include locations in Grand Rapids, Indianapolis and Santa Monica. To reduce the burden of travel for participants, it is advised to select the nearest clinic when enrolling."
What safety assurances exist for administering ABBV-400 to patients?
"ABBV-400 has not yet been tested extensively in humans, so it received a score of 1 on our scale. This trial is currently at its initial phase and limited data supports the safety and efficacy of this drug."
Are there any vacancies available to participate in this experiment?
"The information hosted on clinicaltrials.gov affirms that recruitment for this trial is currently ongoing; the study was first posted October 13th 2021 and most recently edited September 16th 2022."